– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Orphan Medicinal Products
COPENHAGEN, Denmark, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report third quarter 2026 financial results and provide a business update on Thursday, November 12,
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults
COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has
COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR
COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s
- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement
COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual
COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being
First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injection Milestone marks
– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH®, €55 million for SKYTROFA®, and €8 million for YUVIWEL® – Through July 31, more than 220 unique YUVIWEL patient
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday, August 13,
